Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, is an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP) that is in Phase II clinical trials for knee osteoarthritis pain. The company's product candidates also comprises TLC399, BioSeizer formulation of DSP intended as an intravitreal injection for the treatment of macular edema due to retinal vein occlusion; TLC590, a non-opioid anesthetic for post-surgical pain management; and TLC178, an API to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei City, Taiwan with offices in Hsinchu, Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco, and Tokyo.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone886-2-2655-7377
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.04 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/25/2019 (Estimated)
OptionableNot Optionable
TAIWAN LIPOSOME/S (NASDAQ:TLC) Frequently Asked Questions
What is TAIWAN LIPOSOME/S's stock symbol?
TAIWAN LIPOSOME/S trades on the NASDAQ under the ticker symbol "TLC."
How were TAIWAN LIPOSOME/S's earnings last quarter?
TAIWAN LIPOSOME/S (NASDAQ:TLC) announced its quarterly earnings data on Tuesday, July, 30th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.03. The firm earned $0.66 million during the quarter, compared to analyst estimates of $0.39 million. TAIWAN LIPOSOME/S had a negative net margin of 406.97% and a negative return on equity of 155.55%. View TAIWAN LIPOSOME/S's Earnings History.
When is TAIWAN LIPOSOME/S's next earnings date?
What price target have analysts set for TLC?
5 brokers have issued 12-month price targets for TAIWAN LIPOSOME/S's stock. Their predictions range from $10.00 to $11.00. On average, they expect TAIWAN LIPOSOME/S's stock price to reach $10.6667 in the next year. This suggests a possible upside of 112.9% from the stock's current price. View Analyst Price Targets for TAIWAN LIPOSOME/S.
What is the consensus analysts' recommendation for TAIWAN LIPOSOME/S?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TAIWAN LIPOSOME/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TAIWAN LIPOSOME/S.
What are Wall Street analysts saying about TAIWAN LIPOSOME/S stock?
Here are some recent quotes from research analysts about TAIWAN LIPOSOME/S stock:
- 1. According to Zacks Investment Research, "Taiwan Liposome Company Ltd. is a specialty pharmaceutical company. It focuses on development and commercialization of novel nanomedicines designed to target unmet medical need in pain management, ophthalmology and oncology. The company's product pipeline consists of TLC599, TLC590, TLC399 and TLC178 which are in clinical stage. Taiwan Liposome Company Ltd. is headquartered in Taipei City, Taiwan. " (7/13/2019)
- 2. HC Wainwright analysts commented, "Our $10 target is based on a 60% probability of success weighted DCF. Our model assumes approval and launch in the U.S. of TLC599 for knee OA, self-sold by TLC. We do not include any other explicit pipeline value in our model, nor do we include any value for potential ex-US sales or royalties beyond the current small base business. We project TLC profitability in 2025 and peak sales around $500M in 2030. Our DCF uses a 12.5% WACC-based discount rate, and negative 10% terminal growth beyond 2030." (4/18/2019)
- 3. Cantor Fitzgerald analysts commented, "We believe TLC’s expertise in applying liposome science is creating novel medicines with enhanced properties that target areas of unmet medical need. The company’s liposome-based formulation technologies, in our view have the potential to improve the pharmacologic and therapeutic potential of approved pharmacophores to treat various medical disorders. The company has developed four diverse lead product candidates in pain management, ophthalmology, and oncology that are advancing into late-stage clinical trials." (3/18/2019)
Has TAIWAN LIPOSOME/S been receiving favorable news coverage?
Media headlines about TLC stock have trended somewhat negative on Sunday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TAIWAN LIPOSOME/S earned a news impact score of -1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for TAIWAN LIPOSOME/S.
Who are some of TAIWAN LIPOSOME/S's key competitors?
Some companies that are related to TAIWAN LIPOSOME/S include MacroGenics (MGNX), Vectura Group (VEGPF), Revance Therapeutics (RVNC), TG Therapeutics (TGTX), Synthorx (THOR), Aurinia Pharmaceuticals (AUPH), DiaMedica Therapeutics (DMCAF), Flexion Therapeutics (FLXN), Organogenesis (ORGO), Myovant Sciences (MYOV), Lannett (LCI), Akebia Therapeutics (AKBA), Basilea Pharmaceutica (BPMUF), Retrophin (RTRX) and Achillion Pharmaceuticals (ACHN).
What other stocks do shareholders of TAIWAN LIPOSOME/S own?
Who are TAIWAN LIPOSOME/S's key executives?
TAIWAN LIPOSOME/S's management team includes the folowing people:
- Dr. Keelung Hong, Founder, Chairman & CEO (Age 75)
- Mr. Zhi-Hong Yeh M.B.A., Pres & GM (Age 46)
- Ms. Ru-Yun Lin M.B.A., CFO and VP of Fin. & Admin. (Age 53)
- Dr. Wenji Chen M.B.A., Ph.D., VP of Corp. Devel. Division (Age 59)
- Dr. Luke Guo Ph.D., Chief Scientific Advisor & Member of Scientific Advisory Board
When did TAIWAN LIPOSOME/S IPO?
(TLC) raised $29 million in an IPO on the week of November 19th 2018. The company issued 5,000,000 shares at $5.80 per share. Cantor served as the underwriter for the IPO and CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw & Company (UK) Ltd. were co-managers.
How do I buy shares of TAIWAN LIPOSOME/S?
Shares of TLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is TAIWAN LIPOSOME/S's stock price today?
One share of TLC stock can currently be purchased for approximately $5.01.
How big of a company is TAIWAN LIPOSOME/S?
TAIWAN LIPOSOME/S has a market capitalization of $159.62 million and generates $2.04 million in revenue each year. The company earns $-29,450,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. View Additional Information About TAIWAN LIPOSOME/S.
What is TAIWAN LIPOSOME/S's official website?
How can I contact TAIWAN LIPOSOME/S?
TAIWAN LIPOSOME/S's mailing address is 2F 3 YUANQU STREET NANGANG DISTRICT, TAIPEI CITY F5, 11503. The company can be reached via phone at 886-2-2655-7377 or via email at [email protected]
MarketBeat Community Rating for TAIWAN LIPOSOME/S (NASDAQ TLC)
MarketBeat's community ratings are surveys of what our community members think about TAIWAN LIPOSOME/S and other stocks. Vote "Outperform" if you believe TLC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLC will underperform the S&P 500 over the long term. You may vote once every thirty days.
